Liquidia raising $75M in stock offering, to acquire rare disease drug firm

RESEARCH TRIANGLE PARK – Liquidia Technologies is acquiring and then merging with a firm focused on pharmaceutical products to treat rare diseases and also is raising $75 million in a stock offering.

Liquidia disclosed both moves on Monday.

Liquidia is acquiring RareGen in an all-stock deal. The combined firm will be called Liquidia.

Read more about the acquisition online.